HER2

The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.

Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.

At the AACR annual meeting, researchers presented results from the Phase II SUMMIT trial investigating the pan-HER-targeted therapy neratinib.

The new system emphasizes the importance of tumor biology as an important prognostic indicator for women who undergo neoadjuvant therapy, the researchers said.

Data showed that patients who had pathologic complete response in the neoadjuvant setting after treatment with a regimen containing Genetech's Perjeta experienced better progression-free and disease-free survival.

NEW YORK (GenomeWeb) – Roche this week announced plans to acquire Seragon Pharmaceuticals, aiming to bolster its own breast cancer pipeline and improve the standard of care for hormone receptor-positive breast cancer.

A new study using gene expression profiling to divide patients from an adjuvant trastuzumab (Herceptin) clinical trial into subgroups based on their response to the drug has shown that adjuvant treatment in addition to chemotherapy might be effective even in HER2-negative patient

The American Society for Clinical Oncology and the College of American Pathologists have jointly issued updated guidelines in which they continued to recommend that oncolo

The US Food and Drug Administration has accepted a supplemental biologics license application for Perjeta (pertuzumab) as a neoadjuvant treatment for women with HER2-positive, early-stage breast cancer, Roche subsidiary Genentech announced this week.

A flurry of recently published peer-reviewed papers has demonstrated the growing breadth and diversity of applications for Bio-Rad's QX100 Droplet Digital PCR system.

Pages

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.